Organ-on-Chip Market By Type (Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, Lung on chip): Global Opportunity Analysis and Industry Forecast, 2020-2030

Organ-on-Chip Market By Type (Heart on chip, Human on chip, Intestine on chip, Kidney on chip, Liver on chip, Lung on chip): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global organ-on-chip market was valued at $103.44 million in 2020, and is estimated to reach $1,559.2 million by 2030, growing at a CAGR of 31.1% from 2021 to 2030. 

Organ-on-chip is designed to replicate the natural physiology and mechanical stress that cells in the human body encounter.

The chips have real human cells lining them, and their tiny fluidic channels mimic blood and air movement in the human body. The chips flexibility allows them to mimic breathing patterns and muscle contractions. Each organ chip, including the lung, liver, intestine, or brain, is approximately the size of an battery that is typically used in small electronic devices. . Such devices produce multiple levels of tissues and organ functionalities, which are not possible using conventional 2D and 3D culture systems. Organ-on-chip offers a wide range of applications such as diseases modelling, patient stratification, and phenotypic screening. Researchers can see the organ's operation, behavior, and response at the cellular and molecular level because to the chip's transparency.

This market is majorly driven by increase in prevalence of the chronic disease across the globe, which, in turn, increases the demand for medications, leading to drug discovery, drug development, and animal testing. However, organ-on-chips are looked on as an alternative for animal testing due to stringent regulatory guidelines and its complexity. Wide availability of 3D models for in vitro testing ,including lung-on-chip, heart-on-chip, liver-on-chip, and brain-on-chip is significantly driving the growth of the market.

Furthermore, in May 2021, the U.S. Food and Drug Administration (FDA) extendedits research collaboration with CN Bio Innovations Limited, one of the leading developers of single and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, for another three years to investigate the lung-on-a-chip model for inhaled drug evaluation applications.

Furthermore, growth in demand for personalized medicine, rise in pharmaceutical & biotechnology R&D, and government funding for various drugs, clinical trials for novel entities, and repurposing of the drugs are  expected to drive the organ-on-chip market in the forecast period.

Market players have invested in developing organ-on-chip products for lung, heart, kidney, brain, liver, and gut that can aid in several disease treatments. For instance, Nortis Inc. offers ParVivo microfluidic chips system is the world’s first and only pre-seeded chip platform, where researchers can purchase chips that have engineered functional living human tissues on them. Emulate Inc., one of the leaders in the organ-on-chip market industry offers colon-chip, duodenum-chip, brain-chip, lung-chip, kidney-chip, and liver-chip to investigate its mechanisms and evaluate its drug efficacy. These wide range of products offering by market players have further increased accessibility of organ-on-chip across different regions, thus fueling the market growth.

However, high cost of the organ chip device and the development of organ-on-chip technology is still in its nascent stage, and is expected to restrain growth of the market. Furthermore, presence of a variety of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for the market growth during the forecast period. Conversely, considerable rise in healthcare expenditure across the globe led to rise in the market growth. Emerging economies possess high potential for organ-on-chip. Growth in awareness for animal safety during clinical trials and stringent guidelines by regulatory authorities for these trials surge the organ-on- chip market and is being regarded as a promising technology for the alternative to animal testing and is expected to boost the organ-on-chip market size.

The organ-on-chip market is segmented on the basis of type, and region. Depending on type, it is classified into heart-on-chip, human-on-chip, intestine-on-chip, kidney-on-chip, liver-on-chip, and lung-on-chip. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major players profiled in the report are AxoSim Technologies LLC, BICO Group AB(Visikol), CN Bio Innovations Limited, Elveflow, Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc., and Tara Biosystems.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the organ-on-chip market analysis from 2020 to 2030 to identify the prevailing organ-on-chip market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the organ-on-chip market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global organ-on-chip market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments


By Type

Heart on chip
Human on chip
Intestine on chip
Kidney on chip
Liver on chip
Lung on chip

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa

Key Market Players

AxoSim Technologies LLC
BICO Group AB(Visikol)
CN Bio Innovations Limited
Elveflow
Emulate, Inc.
Insphero AG
Mimetas B.V.
Nortis Inc.
Organovo Holdings, Inc.
Tara Biosystems